Qualcomm and Novartis to invest up to $100M in health technology companies

 

Qualcomm Ventures and Novartis have established a joint investment company that will invest up to $100 million to support early stage companies with technologies, products or services that "go beyond the pill.” 

The partnership pairs Qualcomm’s background in digital and mobile technology with Novartis’ specialty in medicine and drugs. To quality for investment funds, companies must demonstrate that their technologies provide benefits to physicians and/or patients, according to a press release.

The types of technologies of particular interest to the newly formed company include telephone enabled devices, mobile applications and wearable devices.

"By working with Qualcomm Ventures, Novartis sees the opportunity to take a greater leadership role in introducing new mobile or digital technologies that have the potential to change the practice of medicine and bring more breakthroughs with real benefits to patients and society," said David Epstein, division head, Novartis Pharmaceuticals, in a statement.

 

 

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”